Biomarkers (2)
B1 – B32
- B1: Onco-gene induced cellular senescence: a 1H NMR based metabolomics study
- B2: Quantitative, multiplexed, Quantum dot immunohistochemistry for clinical trial use
- B3: Proteomic identification of two urinary proteins with prognostic value in patients with renal cell carcinoma
- B4: Raman and fluorescence spectroscopy of blood plasma in the diagnosis of cancer
- B5: MicroRNA expression and profiling of bladder cancer
- B6: Functional genomic annotation of microtubule stabiliser response defines chromosomal instability as a determinant of taxane sensitivity in vivo
- B7: Genes associated with chemosensitivity or genotype in oligodendroglial tumours
- B8: A single UK centre study of temozolomide and radiotherapy in glioblastoma patients
- B9: Promoter hypermethylation in urothelial carcinomas of young and elderly patients: a comparative study
- B10: The pancreatic cancer serum proteome: highly abundant proteins and associated biomarkers
- B11: GINS proteins as candidate markers for cancer diagnosis
- B12: Translational studies on anti-TNF-α antibodies in Renal Cell Carcinoma (RCC)
- B13: DNA quantification of exfoliated colonocytes as a novel screening tool for colorectal neoplasia and inflammation
- B14: Development of a “composite serum biomarker” model to predict presence of colorectal cancer using artificial neural networks: an example with IGF-related peptides
- B15: Measurement of angiogenic biomarkers in human plasma by BD FacsArray Cytometric Bead Technology
- B16: Differential risk of bowel cancer – Apoptosis and mitosis in the normal mucosa of those with adenomatous and metaplastic Polyps, adenocarcinomas and diverticular disease
- B17: Evaluation of the alkaline comet assay as a predictive test of bladder cancer treatment
- B18: Using a mouse model of colon cancer in the search for a genetic signature of response to anti epidermal growth factor receptor therapy
- B19: VORTEX-BIOBANK: Translational tissue banking for the development of molecular profiles to individualise patient treatment
- B20: Systematic optimisation of in vivo imaging of αvβ6 in cancer
- B21: Characterisation of an autochthonous model of pancreatic cancer by in-vivo and ex-vivo magnetic resonance methods: a preliminary study
- B22: Molecular correlates of fatigue in patients undergoing breast radiotherapy
- B23: The SK1/S1P pathway as a potential diagnostic/prognostic marker in prostate cancer
- B24: Expression of Cutaneous Fatty Acid- Binding Protein (C-FABP) in prostate cancer: Potential prognostic marker and target for tumourigenicity-suppression
- B25: The expression and function of 2-cys peroxiredoxins in prostate cancer progression to hormone refractory disease
- B26: Effect of diet and lifestyle on DNA damage in mothers and assessment of exposure to the foetus
- B27: Characterisation of RASSF8 and methylation analysis of chromosome 3 genes in childhood acute lymphoblastic leukaemia using a NotI array
- B28: TM9SF2, a novel cell surface potential target in breast cancer
- B29: Biognosis – Development of a novel point of care diagnostic for cancer detection
- B30: DASL ™ (cDNA Mediated Annealing Selection and Ligation) assay for molecular marker studies with formalin fixed paraffin (FFPE) embedded tissue in breast cancer
- B31: Evaluating gene expression in FFPE tissues using DASL®: validation by quantitative real-time PCR and immunohistochemistry
- B32: Geminin regulates DNA replication and predicts clinical outcome in breast cancer
